FDA Approves Cancer Breakthrough Pain Drug with Safeguards

The Food and Drug Administration has approved a new opiate drug for severe breakthrough cancer pain.  However, Onsolis® will only be available through a restricted distribution program. As part of an FDA-required Risk Evaluation and Mitigation Strategy, or REMS, only health care providers, pharmacies, and patients registered with the FOCUS program will be able to prescribe, dispense,…  Read More